HIGHLIGHTS
- What: As SGLT2 inhibitors become more widely used for various conditions, healthcare providers need to be aware of euDKA as a rare side effect of SGLT2 inhibitor therapy.
- Who: Empagliflozin-d Euglycemic Diabetic and colleagues from the Consortium, Las Vegas, USA have published the article: Review began 06/07/2024 Review ended 07/31/2024 Published 08/07/2024 © Copyright, in the Journal: (JOURNAL) of August/07,/2024
SUMMARY
Euglycemic diabetic ketoacidosis (EuDKA) is a rare complication of sodium-glucose co-transporter 2 (SGLT2) inhibitors that can sometimes go unnoticed in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.